Our unpublished data provide evidences that upon stimulation with GPER agonist (G-1), activation of the downstream effectors of GPER signaling such as ERK and AKT was weakened after down-regulation of NHERF in breast cancer cells. This evidence concerns the gene GPER1 and breast carcinoma.